Uncategorized
This week in Drug Discovery (17-21 August 2026)
News round-up for 17-21 August by Megan Thomas, Content Team at DDW.
This week’s news roundup covers new therapeutic approaches moving towards or through clinical development, alongside advances in drug discovery and the investment landscape supporting biotech innovation.
The top stories:
DDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows
The Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place on 30 September 2026, will bring together experts from across the drug discovery ecosystem to examine the scientific, operational and commercial developments shaping the future of early-stage drug discovery. Following the announcement of the preliminary speaker lineup, we are now revealing further details of three of the four sessions featured in the programme.
Immunotherapy for Parkinson’s gets FDA Fast Track Designation
AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD).
First patient receives novel heavy-chain-only antibody
Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours.
Partnership supports radiopharmaceutical solid tumour development
Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours.
New drug target discovered for acute myeloid leukaemia
Researchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects.
The post This week in Drug Discovery (17-21 August 2026) appeared first on Drug Discovery World (DDW).